Open Access<p>Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4<sup>+</sup>T Response</p>
Author(s) -
Yue Wu,
Weifeng Shi,
Honghai Wang,
Jiawei Yue,
Yi-Jie Mao,
Wei Zhou,
Xinagmin Kong,
Qiqiong Guo,
Lirong Zhang,
Peng Xu,
Yuyue Wang
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s268282
Subject(s) - innate lymphoid cell , inflammation , bronchoalveolar lavage , immunology , cytokine , lung , interleukin 33 , medicine , chemistry , immune system , acquired immune system , interleukin
Asthma has been regarded as an inflammatory disease, and group 2 innate lymphoid cells (ILC2s) are implicated in asthma pathogenesis. However, no strategy is available to block ILC2s function. Efficiency is also limited due to the use of systemic or subcutaneous routes of administration. The purpose of this study was to investigate the effects of nanoparticles targeting suppression of tumorigenicity 2 (ST2), which is the ILC2 receptor, to alleviate lung inflammation in the murine model of asthma.